by Louis Navellier | October 13, 2011 3:01 pm
Pharmaceutical stocks and drugmakers are theoretically recession-proof businesses, since folks will do everything they can to maintain their quality of life through medication and treatments. Still, not all pharma companies are created equal and there are clear winners and losers in this health care sector.
I watch more than 5,000 publicly traded companies with my Portfolio Grader tool, ranking companies by a number of fundamental and quantitative measures. This week I’ve got seven pharma stocks to sell.
Here they are, in alphabetical order. Each one of these stocks gets a “D” or “F” according to my research, meaning it is a “sell” or “strong sell.”
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) develops and markets products for urologists, endocrinologists, hand surgeons and other specialty physicians. AUXL has had a 23% slide, year-to-date.
Endo Pharmaceuticals (NASDAQ:ENDP) deals with branded products, generics, devices and services, and is the developer of branded drugs you may recognize such as Percocet and Lidoderm. While other competitive pharma stocks have thrived in this tough economic landscape, ENDP is down 19% year-to-date.
Hospira Inc. (NYSE:HSP) is a specialty big pharma stock that offers a portfolio of products including oncology injectables. Since the start of 2011, HSP has slid 31%, compared to slight losses by the broader markets.
Nektar Therapeutics (NASDAQ:NKTR) is a clinical-stage biopharmaceutical company that develops products for oncology and pain relief. NKTR has dropped 61% year-to-date, while some of its competitors have posted gains for the year.
Par Pharmaceutical (NYSE:PRX) is famous for developing, licensing, manufacturing, marketing and distributing generic drugs. Since that start of 2011, PRX has lost 23%, compared to much smaller losses by the broader markets.
Teva Pharmaceutical Industries (NASDAQ:TEVA) is a global pharmaceutical company that produces generic drugs for a variety of ailments. TEVA has performed worse than the broader markets this year and is down 25% for 2011.
Warner Chilcott (NASDAQ:WCRX) deals mostly with women’s healthcare, gastroenterology, dermatology and urology. WCRX has lost 30% year-to-date, much to the dismay of the company’s shareholders.
Get more analysis of these picks and other publicly-traded stocks with Louis Navellier’s Portfolio Grader tool, a 100% free stock-rating tool that measures both quantitative buying pressure and eight fundamental factors.
Source URL: http://investorplace.com/2011/10/7-big-pharma-stocks-to-sell-auxl-endp-hsp-nktr-prx-teva-wcrx/
Short URL: http://invstplc.com/1nELcmj
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.